Chemotherapy Plus Anti-PD-1 or Anti-PD-L1 in Advanced PD-L1–Negative Squamous Cell Lung Carcinoma: A Systematic Review and Meta-Analysis
- 21 May 2025
- journal article
- review article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 26 (6) , e361-e373
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON StudyClinical Lung Cancer, 2024
- A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)Cancer Cell, 2024
- Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trialESMO Open, 2023
- Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysisClinical & Experimental Metastasis, 2023
- Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 TrialJournal of Thoracic Oncology, 2023
- Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 TrialJournal of Thoracic Oncology, 2022
- Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)Journal of Thoracic Oncology, 2021
- Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III TrialJournal of Thoracic Oncology, 2020
- Current and Emergent Therapy Options for Advanced Squamous Cell Lung CancerJournal of Thoracic Oncology, 2018
- Metastatic sites and survival in lung cancerLung Cancer, 2014